College of Traditional Chinese Medicine, Jilin Agriculture Science and Technology College, Jilin 132101, China; Jilin Provincial Health Products and Medical Materials Technology Innovation Center, Changchun 130118, China.
College of Traditional Chinese Medicine, Jilin Agriculture Science and Technology College, Jilin 132101, China.
Int J Biol Macromol. 2024 Feb;259(Pt 1):129160. doi: 10.1016/j.ijbiomac.2023.129160. Epub 2024 Jan 4.
The healing of wounds in diabetics is commonly delayed by recurring infections and persistent inflammation at the wound site. For this reason, we conducted a study using the electrospinning technique to create nanofiber membranes consisting of polyvinylpyrrolidone/chitosan (PVP/CS) and incorporated dihydromyricetin (DHM) into them. Infrared Fourier transform spectroscopy and scanning electron microscopy were used to analyze the nanofiber membrane. Experimental results in vitro have shown that PVP/CS/DHM has exceptional properties such as hydrophilicity, porosity, water vapor transport rate, antioxidant capacity, and antibacterial activity. Moreover, our study has demonstrated that the application of PVP/CS/DHM can significantly improve wound healing in diabetic mice. After an 18-day treatment period, a remarkable wound closure rate of 88.63 ± 1.37 % was achieved. The in vivo experiments revealed that PVP/CS/DHM can promote diabetic wound healing by suppressing the activation of TLR4/MyD88/NF-κB signaling pathway and enhancing autophagy-related protein as well as CD31 and HIF-1α expression in skin tissues. This study showed that PVP/CS/DHM is a promising wound dressing.
糖尿病患者的伤口愈合通常会因伤口部位反复感染和持续炎症而延迟。出于这个原因,我们使用静电纺丝技术进行了一项研究,制造了由聚乙烯吡咯烷酮/壳聚糖(PVP/CS)组成的纳米纤维膜,并将二氢杨梅素(DHM)掺入其中。使用红外傅里叶变换光谱和扫描电子显微镜对纳米纤维膜进行了分析。体外实验结果表明,PVP/CS/DHM 具有出色的性能,如亲水性、多孔性、水蒸气传输率、抗氧化能力和抗菌活性。此外,我们的研究表明,PVP/CS/DHM 的应用可以显著改善糖尿病小鼠的伤口愈合。经过 18 天的治疗期,实现了 88.63±1.37%的显著伤口闭合率。体内实验表明,PVP/CS/DHM 可以通过抑制 TLR4/MyD88/NF-κB 信号通路的激活以及增强皮肤组织中自噬相关蛋白以及 CD31 和 HIF-1α 的表达来促进糖尿病伤口愈合。这项研究表明,PVP/CS/DHM 是一种有前途的伤口敷料。
Nanomaterials (Basel). 2025-6-11
Front Bioeng Biotechnol. 2024-8-5